April 1, 2016

GHIT Annual Partners Meeting 2016: Event Time Change and Speakers Confirmed for Session 1

 Please note that the event time of the GHIT Annual Partners Meeting 2016 has shifted to begin one hour later. We apologize for any inconvenience caused.


【Updated time】June 7, 2016 14:00-16:30

【Previous time】June 7, 2016 13:00-16:30


 We are pleased to announce speakers for Session 1: GHIT on the Ground - Innovation & Impact.


- Muhidin Kassim Mahende, MD Clinical Research Officer, Ifakara Health Institute, Tanzania

- Hiroyuki Kojima, PhD Research Fellow, Pharmaceutical Research and Technology Labs, Astellas Pharma Inc.

- Sodiomon Bienvenu Sirima, MD, PhD Executive Director, Centre National de Recherche et de Formationsur le Paludisme (CNRFP), Burkina Faso

- Toshihiro Horii, PhD Professor, Research Institute for Microbial Diseases, Osaka University


Dr. Mahende and Dr. Kojima will share the pediatric praziquantel formulation development story for the treatment of schistosomiasis. Praziquantel is the standard recommended treatment for schistosomiasis, a disease that affects millions. Until now, no pediatric formulation has existed, and the size and bitter taste of the traditional oral tablets have meant that younger children run a significant risk of choking. The new formulation candidates are much smaller and can be dispersed in water. The Phase 2a/b trial in which our speakers are engaged tests the pediatric formulation with proven efficacy and safety in preschool-aged children, infants, and toddlers for acceptable taste properties and its ability to withstand the challenges presented by a tropical climate. The resulting clinical data will enable registration of the final formulation in endemic countries where the medication is urgently needed.


Dr. Sirima and Dr. Horii will offer perspectives and insight on the clinical development of the BK-SE36 malaria vaccine candidate, sharing results from recent tests. The BK-SE36 vaccine candidate will undergo a phase Ib clinical trial in Burkina Faso. The aim is to (i) compare the clinical trial results from Burkina Faso with those from a previous clinical trial conducted in Uganda, (ii) test in a younger age group (0-5 years old) that has not yet been included in any of the other clinical trial testing of BK-SE36, and (iii) generate additional information on safety, immunogenicity, and possible efficacy.